Understanding the Link Between Tysabri and Progressive Multifocal Leukoencephalopathy
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Focused Risk Communication
If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare brain infection is a known complication of the drug, but understanding the symptoms and monitoring protocols can help manage the risk. Building on decades of pharmacovigilance research, this page provides a clear overview of what PML is, how it relates to Tysabri, and what patients should watch for.
Tysabri and PML: Medical Evidence and Risk Factors
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, highlighting that the drug increases the risk of PML and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and speech difficulties. Diagnosis is typically confirmed by brain MRI and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocyte migration into the brain, thereby reducing immune surveillance and allowing JC virus reactivation and replication in oligodendrocytes. This immunosuppressive effect is dose- and duration-dependent, explaining the increased risk with longer therapy. For patients who develop PML after Tysabri exposure, the timeline between exposure and documented harm can vary. PML onset has been reported after a few months to several years of treatment, with the highest risk after two years of continuous therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once PML is suspected, Tysabri must be discontinued immediately, and treatment may include plasma exchange to accelerate drug clearance, along with supportive care and, in some cases, antiviral therapy such as mirtazapine or mefloquine, though evidence for these interventions is limited.
Statute of Limitations for Tysabri PML Claims in New Jersey
From a legal and settlement perspective, patients affected by Tysabri-associated PML in New Jersey must consider the statute of limitations for filing claims. In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when symptoms first appeared or when a diagnosis was confirmed. Given the latency period between Tysabri exposure and PML onset, careful documentation of treatment dates, symptom onset, and diagnosis is critical. Settlement considerations often involve evaluating the adequacy of warnings provided to patients and healthcare providers. The FDA boxed warning and TOUCH program requirements represent formal risk communication, but plaintiffs may argue that these warnings were insufficient or that the risks were not adequately conveyed to individual patients, particularly those with lower perceived risk based on anti-JCV antibody status or treatment duration. Risk anchors for affected patients include the severity of PML outcomes (death or severe disability), the burden of long-term care, and the potential for lost wages and medical expenses. Settlement amounts may vary based on factors such as the patient's age, baseline health, degree of disability, and the strength of evidence linking Tysabri to the PML diagnosis. Legal counsel experienced in pharmaceutical litigation can help navigate the statute of limitations and assess the viability of claims based on New Jersey law. In summary, Tysabri-associated PML is a serious adverse event with established risk factors and a mechanistic basis in immune modulation. Patients and healthcare providers must remain vigilant for early signs of PML, and those affected should promptly seek legal advice to ensure compliance with New Jersey's statute of limitations. The adequacy of warnings and the timeline of exposure and harm are central to any settlement-related considerations. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in New Jersey?
In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when symptoms first appeared or when a diagnosis was confirmed. It is crucial to document treatment dates, symptom onset, and diagnosis to ensure timely filing.
What are the primary risk factors for PML in Tysabri-treated patients?
Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating and continuing therapy.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.